Triple Negative Breast Cancers
HPV infection and triple negative breast cancers: an Italian case control study
... categorize breast cancers in different prognostic sub- groups (luminal A, luminal B, HER2 overexpressing, and triple negative breast cancers [TNBC]), with distinct therapeutic ...
5
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
... Triple-negative breast cancers (TNBCs) are defined as a group of breast cancer characterized by lacking of estrogen receptor (ER), progesterone receptor (PgR) and human epi- dermal ...
11
FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing SOD2 and IL6
... for breast cancer subtyping, especially for triple negative breast cancer identification is crucial for improving the treatment outcome of such ...characterizing triple negative ...
12
Clinicopathologic features of triple negative breast cancers: an experience from Pakistan
... Basal cancers have a unique demographic and racial profile, with high rate of occurrence contemplated in Asian and African American women ...receptor negative breast cancers in Asian women ...
9
Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers
... Triple-negative breast cancers (TNBCs) have been classified as a breast carcinoma subgroup which is negative for estrogen receptor (ER), progesterone receptor (PgR) and HER2 ...
11
CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers
... Doxorubicin and Cisplatin are the frontline therapeutics for treatment of the triple negative breast cancers (TNBCs). Emergence of drug-resistance often contributes to failure of drugs and ...
19
Original Article Topoisomerase IIα and BRCA1 expression as predictive factors for anthracycline-based adjuvant chemotherapy response and prognosis in triple-negative breast cancers
... adducts with DNA; and 4) bleomycin, which directly damages DNA by inducing double- strand breaks [14-16]. BRCA1 was recently shown to be a predictive factor in response to anthracycline-based regimens. Because anth- ...
10
Spatially distinct tumor immune microenvironments stratify triple negative breast cancers
... Detailed protocols and procedures are available in the Supplemen- tal Methods. Samples were collected from patients undergoing breast surgeries at the MUHC between 1999 and 2012. For the purposes of this study, ...
17
CDCP1 is a novel marker of the most aggressive human triple- negative breast cancers
... epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities—ie, migration, invasion, ...
17
BRCA1 IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
... DCIS: ductal carcinoma in situ ; DFS: disease-free survival; EGF: epidermal growth factor, NRG1, neurogulin 1; EGFR: ErbB2 and ErbB3, epidermal growth factor receptor 1, 2 and 3, respectively; EMT: epithelial to ...
18
Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers
... cases/patients) (4) Invasive Ductal Cancer, PAM50 Her2-enriched (51 cases/patients), (5) Invasive Ductal Cancer, PAM50 Basal-like (107 cases/patients) and (6) Triple-negative breast tumors (82 ...
26
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
... sensitive breast cancer models in vitro and in vivo, indicating that treatment- associated increase in P-AKT is not a marker of resistance but rather of sensitivity ...
14
Epigenetic silencing of CREB3L1 by DNA methylation is associated with high grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers
... cDNA using Superscript II Reverse Transcriptase and oligo-dT primers (Invitrogen) according to the supplier’s instructions. CREB3L1 expression was measured by quantitative real-time PCR performed using TaqMan probes ...
21
Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)
... densitometry) following triplicate independent TBXA2R siRNA knockdowns (Figure 6A). The increase in DNA damage following TBXA2R knockdown was also demonstrated by foci counts following immunofluorescent staining for ...
15
Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers
... on breast cancer patient outcomes such as race, age, receptor- status, molecular signatures and so ...with breast cancer, there is an estimated 20–40% chance of the breast cancer being ...
11
Classification of triple-negative breast cancers based on Immunogenomic profiling
... Triple-negative breast cancer (TNBC) is a breast cancer subtype that lacks the expression of hormone receptors (estrogen receptor (ER) and progesterone receptor (PR)) and human epidermal ...
13
Profiling molecular regulators of recurrence in chemorefractory triple negative breast cancers
... published interactions to predict up- or downregulation of entities upstream of multiple gene expression differences (Ingenuity Systems, www.ingenuity.com). We identified 37 regulators with potent changes between time ...
15
Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers
... Resident mesenchymal stem cells (MSCs) promote cancer progression. However, pathways and mechanisms involved in recruiting MSCs into breast tumors remain largely undefined. Here we show that geminin-dependent ...
21
The association of genomic lesions and PD 1/PD L1 expression in resected triple negative breast cancers
... of triple-negative breast cancer (TNBC) genomes makes TNBC a highly favorable model to test genomic correlates of PD-1 and PD-L1 expression ...
15
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
... showing that TKI inhibition is often more effective in tumors harboring genomic amplified kinases, such as HER2-amplified breast cancers and MET-amplified lung cancers [45, 46]. Even though amplified ...
13